by Ariana Pelosci
An individualized starting dose of niraparib, determined by weight and platelet count continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status.
An
by Lindsay Fischer
New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.
Patients with BRCA1/–mutated, platinum-sensitive, recurrent ovarian cancer who needed to reduce
by Alison Kanski
NEW YORK – An investigational AstraZeneca drug that showed activity at a range of doses across differently mutated cancers with limited toxicity exemplifies the versatility of next-generation PARP1 inhibitors, according to researchers at the American Society for … Read more
by Ariana Pelosci
A significant improvement in progression-free survival was observed in the phase 3 ATHENA-MONO trial with first-line maintenance rucaparib vs placebo in patients with advanced ovarian cancer.
Progression-free survival (PFS) was significantly improved with first-line rucaparib (Rubraca) as
by Ariana Pelosci
Adverse effects associated with treatment with olaparib that led to dose reductions and interruptions did not impact survival benefit for patients with platinum-sensitive ovarian cancer.
Patients with platinum-sensitive recurrent ovarian cancer who experienced adverse effects (AEs) during
by Jonathan Goodman, MPhil
Hispanic and Non-Hispanic Black patients were significantly underrepresented, but Asian/Pacific Islander patients were overrepresented.
Clinical trials of PARP inhibitors in patients with ovarian cancer do not accurately reflect the racial and ethnic makeup of the real-world … Read more
— Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed
Patients with relapsed platinum-sensitive ovarian cancer had significant improvement in progression-free survival (PFS) when retreated with the PARP inhibitor olaparib … Read more
A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients with breast cancer and other malignancies.… Read more
For a second time, researchers will test an antibiotic discovered in the 1950s as a potential treatment for cancer.
The first attempt to study the drug, novobiocin, in patients with cancer was a small clinical trial conducted 30 years ago. … Read more
The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.
The combination of ceralasertib and olaparib (Lynparza) induced clinical activity and was well tolerated in … Read more
RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.
By … Read more
By Chase Doyle
The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the … Read more
By Chase Doyle
Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT … Read more
Modest improvement in PFS with rucaparib but worse outcome for reversion mutation.
By Charles Bankhead
A PARP inhibitor slowed progression of recurrent, advanced BRCA-positive ovarian cancer as compared with standard chemotherapy, a randomized trial showed.
Treatment with rucaparib (Rubraca) … Read more
Receiving a cancer diagnosis can be overwhelming. But the more you know about your specific situation, the better.
By
Every year, more than 21,000 women in the United States are diagnosed with ovarian cancer. In about half of
… Read moreIncidence of MDS/AML under 1%, but further investigation warranted as indications broaden
By Leah Lawrence
Although rare, poly-ADP ribose polymerase (PARP) inhibitors were associated with an increased risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and occurred even … Read more
By Caroline Hopkins
Using organoids that closely model certain features of ovarian tumors, researchers have identified and tested treatment combinations that may benefit patients, many of whom experience acquired or de novo resistance to PARP inhibitors.
In a study recently … Read more
When I learned this summer that the clinical trial of the cancer drug that seems to be keeping me alive had unexpectedly shut down, I discovered the murky rules governing drug trials and the stressful confusion they … Read more
By Andrew D. Bowser
However, trials investigating retreatment are underway, so this recommendation may change.
The guidelines, from … Read more
By Savannah Demko
Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.
“Preclinical studies suggest the potential for synergy between … Read more
